[go: up one dir, main page]

MA69153A1 - Methods of treating splenomegaly - Google Patents

Methods of treating splenomegaly

Info

Publication number
MA69153A1
MA69153A1 MA69153A MA69153A MA69153A1 MA 69153 A1 MA69153 A1 MA 69153A1 MA 69153 A MA69153 A MA 69153A MA 69153 A MA69153 A MA 69153A MA 69153 A1 MA69153 A1 MA 69153A1
Authority
MA
Morocco
Prior art keywords
methods
splenomegaly
treating
treating splenomegaly
therapeutic methods
Prior art date
Application number
MA69153A
Other languages
French (fr)
Inventor
Wayne Philip Rothbaum
Original Assignee
Telios Pharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telios Pharma, Inc. filed Critical Telios Pharma, Inc.
Publication of MA69153A1 publication Critical patent/MA69153A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Processing Of Solid Wastes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

The invention provides therapeutic methods and pharmaceutical compositions for treating splenomegaly in a human subject. In some embodiments, the invention provides therapeutic methods for treating splenomegaly using a BTK inhibitor.
MA69153A 2020-01-08 2021-01-08 Methods of treating splenomegaly MA69153A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062958632P 2020-01-08 2020-01-08

Publications (1)

Publication Number Publication Date
MA69153A1 true MA69153A1 (en) 2025-07-31

Family

ID=76788747

Family Applications (3)

Application Number Title Priority Date Filing Date
MA69153A MA69153A1 (en) 2020-01-08 2021-01-08 Methods of treating splenomegaly
MA63848A MA63848B1 (en) 2020-01-08 2021-01-08 Methods of treatment of splenomegaly
MA57226A MA57226B1 (en) 2020-01-08 2021-01-08 METHODS OF TREATMENT OF SPLENOMEGALY

Family Applications After (2)

Application Number Title Priority Date Filing Date
MA63848A MA63848B1 (en) 2020-01-08 2021-01-08 Methods of treatment of splenomegaly
MA57226A MA57226B1 (en) 2020-01-08 2021-01-08 METHODS OF TREATMENT OF SPLENOMEGALY

Country Status (15)

Country Link
EP (2) EP4000624A1 (en)
JP (1) JP7771064B2 (en)
KR (1) KR20220130151A (en)
CN (1) CN114423457A (en)
AU (1) AU2021205484A1 (en)
BR (1) BR112022013646A2 (en)
CA (1) CA3164063A1 (en)
CO (1) CO2022010592A2 (en)
CR (1) CR20220374A (en)
IL (1) IL294582A (en)
JO (1) JOP20220168A1 (en)
MA (3) MA69153A1 (en)
MX (1) MX2022008490A (en)
TN (1) TN2022000185A1 (en)
WO (1) WO2021142257A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240024314A1 (en) 2020-01-08 2024-01-25 Telios Pharma, Inc. Methods of Treating Splenomegaly
JOP20220168A1 (en) * 2020-01-08 2023-01-30 Telios Pharma Inc Spleen treatment methods
MX2023015097A (en) * 2021-06-16 2024-01-18 Telios Pharma Inc Treatment of symptoms associated with myeloproliferative neoplasms.
WO2023071973A1 (en) * 2021-10-26 2023-05-04 Shenzhen Targetrx, Inc. Fused bicyclic compound for inhibiting activity of tyrosine kinase
CN119677518A (en) * 2022-08-25 2025-03-21 百济神州(苏州)生物科技有限公司 Solid forms comprising (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-A]pyrimidine-3-carboxamide and oxalic acid, compositions thereof, and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016024230A1 (en) * 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, and/or a bcl-2 inhibitor
WO2020192432A1 (en) * 2019-03-27 2020-10-01 广州楹鼎生物科技有限公司 Method for catalytically decomposing lignocellulosic raw material

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
CA2931615A1 (en) * 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
WO2016054491A1 (en) * 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP2021527685A (en) * 2018-06-19 2021-10-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ A novel crystal form of 1-(4-{[6-amino-5- (4-phenoxy-phenyl) -pyrimidine-4-ylamino] -methyl} -4-fluoro-piperidine-1-yl) -propenone, which Salt form, and process for obtaining
TW202128156A (en) * 2019-11-14 2021-08-01 美商夸格智財控股有限公司 Combination of a btk inhibitor and an mdm2 inhibitor for cancer treatment
JOP20220168A1 (en) * 2020-01-08 2023-01-30 Telios Pharma Inc Spleen treatment methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016024230A1 (en) * 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, and/or a bcl-2 inhibitor
WO2020192432A1 (en) * 2019-03-27 2020-10-01 广州楹鼎生物科技有限公司 Method for catalytically decomposing lignocellulosic raw material

Also Published As

Publication number Publication date
BR112022013646A2 (en) 2022-10-04
MA57226A1 (en) 2023-02-28
CO2022010592A2 (en) 2022-10-31
JP2023509968A (en) 2023-03-10
IL294582A (en) 2022-09-01
CR20220374A (en) 2023-01-25
EP4000624A1 (en) 2022-05-25
WO2021142257A1 (en) 2021-07-15
CN114423457A (en) 2022-04-29
TN2022000185A1 (en) 2024-04-01
KR20220130151A (en) 2022-09-26
CA3164063A1 (en) 2021-07-15
EP3980069A4 (en) 2022-08-17
EP3980069A1 (en) 2022-04-13
AU2021205484A1 (en) 2022-08-18
MA63848B1 (en) 2024-10-31
JOP20220168A1 (en) 2023-01-30
MA57226B1 (en) 2023-06-28
MX2022008490A (en) 2022-10-13
MA63848A1 (en) 2024-04-30
JP7771064B2 (en) 2025-11-17

Similar Documents

Publication Publication Date Title
MA69153A1 (en) Methods of treating splenomegaly
MX2022004983A (en) Prodrug compositions and methods of treatment.
MX2020009773A (en) Combination therapy.
MX2023003677A (en) Hsd17b13 inhibitors and uses thereof.
MX2023003678A (en) Hsd17b13 inhibitors and uses thereof.
PH12023552741A1 (en) Psilocybin Compositions, Methods Of Making And Methods Of Using The Same
MX2021002349A (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack.
MX2020011817A (en) Methods for treating lymphoma.
PH12017500392A1 (en) Medical treatments based on anamorelin
WO2022271810A3 (en) Bicyclic peptidyl pan-ras inhibitors
CA3200881C (en) Lactam-modified polypeptide compounds
PH12021552135A1 (en) Methods of treating al amyloidosis
MX2021004207A (en) Use of reboxetine to treat narcolepsy.
MX2023003675A (en) Hsd17b13 inhibitors and uses thereof.
MX2022007113A (en) Lysine-specific histone demethylase inhibitors for the treatment of myeloproliferative neoplasms.
MX2021004396A (en) Methods and compositions for treating oral mucositis.
PH12021551805A1 (en) Treatment of skin lesions and pruritus in prurigo nodularis patients
MX2021007330A (en) Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor.
MX2023015097A (en) Treatment of symptoms associated with myeloproliferative neoplasms.
MX2020008881A (en) Methods of treatment of cancer comprising chk1 inhibitors.
MX2021002590A (en) Methods of using a phenoxypropylamine compound to treat pain.
MX2025004758A (en) Compounds and their use for treatment of hemoglobinopathies
MX2023005156A (en) Therapeutic ph responsive compositions.
EP4234022A3 (en) Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
MX2022008532A (en) Ahr inhibitors and uses thereof.